Cardiotoxicity of doxorubicin/paclitaxel combination in rats: Effect of sequence and timing of administration

Journal of Biochemical and Molecular Toxicology

Volumn 18, Issue 2, 2004, Pages 78-86

  Saad, Sherif Y ^a   Najjar, Tawfeeg A O ^a   Alashari, Mouied ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cardiotoxicity; Doxorubicin; Paclitaxel

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE ISOENZYME; CREATINE KINASE MB; DOXORUBICIN; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; MALONALDEHYDE; NITRATE; NITRITE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; RAT; RAT STRAIN; TISSUE DISTRIBUTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; CREATINE KINASE; CREATINE KINASE, MB FORM; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GLUTATHIONE PEROXIDASE; HEART; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIUM; PACLITAXEL; RATS; RATS, WISTAR;

RATTUS NORVEGICUS;

EID: 2342667565     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.20012     Document Type: Article

References (49)

1. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 2000;294:396-401.
2. Singal PK. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817-828.
3. Sarvazyan NA, Askari A, Huang WH. Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutase. Life Sci 1995;57:1003-1010.
4. Vasquez-Vivar J, Martasex P, Hogg N, Masters BSS, Pritchard KA Jr., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997;36:11293-11297.
5. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 1999;368:421-428.
6. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999;84:257-265.
7. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000;275:33585-33592.
8. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects. Semin Oncol 2001;28(4 Suppl 12): 15-23.
9. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S, Jordan MA, Briand C. Paclitaxel induces release of cytochrome C from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000;60(19):5349-5353.
10. Parker KK, Taylor LK, Atkinson JB, Hansen DE, Wikswo JP, Atkinson B. The effects of tubulin-binding agents on stretch-induced ventricular arrythmias. Eur J Pharmacol 2001;417(1/2):131-140.
11. Markman M, Kennedy A, Webster K, Kulp B, Petreson G, Belinson J. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J Clin Oncol 1998;16:3483-3485.
12. Rose M, Lee FA, Gollerkeri A, d'Andrea E, Psyrri A, Bdolah-Abram T, Burtness BA. The feasibility of high-dose chemptherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplant 2000;26:133-139.
13. Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience. Int J Cancer 2001;93:139-141.
14. Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D' Incalci M. Pharmacokinetic interaction of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 1999;10(4):391-395.
15. Platel D, Pouna P, Bonoron-Adele S, Robert J. Preclinical using the model of isolated perfused rat heart. Toxicol Appl Pharmacol 2000;163(2):135-140.
16. Sparano JA. Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics. Semin Oncol 1999;26(3 Suppl 9):14-19.
17. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-169.
18. Bergemeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem 1978;24:58-73.
19. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62-71.
20. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
21. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
22. Cao Y, Kennedy R, Klimberg VS. Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res 1999;85:178-182.
23. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001;43(3):211-218.
24. Vasquez-Vivar J, Kalyanaraman B, Kennedy MC. Mitochondrial aconitase is a source of hydroxyl radical. An electron spin resonance investigation. J Biol Chem 2000;275:14064-14069.
25. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor kappa β during doxorubicin-induced apoptosis in endothelial cells and myocytes is proapoptotic: The role of hydrogen peroxide. Biochem J 2002;367(Pt 3):729-740.
26. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: Role of oxidant-induced iron signaling in apoptosis. J Biol Chem 2002;277(19):17179-17187.
27. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory protein 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of tumuor therapy. Cancer Res 2001;61(23):8422-9428.
28. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity and bcl-2:Bax ratio. Cancer Res 2002;62(16):4592-4598.
29. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, Braguer D. Paclitaxel targets mitochondria. upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 2002;532(1/2):256-260.
30. Varbiro G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of taxol on free radical formation and mitochondrial permeability transition. Free Radical Biol Med 2001;31(4):548-558.
31. Kirikae T, Ojima I, Fuero-Oderda C, Lin S, Kirikae F, Hashimoto M, Nakanoc M. Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages. FEBS Lett 2000;478(3):221-226.
32. Pae HO, Jun CD, Yoo JC, Kwak HJ, Lee SJ, Kook YA, Park RK, Chung HT. Enhancing and priming of macrophages for superoxide anion production by taxol. Immunopharmacol Immunotoxicol 1998;20(1):27-37.
33. Marczin N, Jiilling T, Papapetroppouulos A, Go C, Catravas JD. Cytoskeleton-dependent activation of the inducible nitric oxide synthase in cultured aortic smooth muscle cells. Br J Pharmacol 1996;118(5):1085-1094.
34. Jum CD, Choi BM, Kim HM, Chung HT. Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J Immunol 1995;154(12):6541-6547.
35. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK 1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275(20):14838-14845.
36. Kim JW, Baek BS, Kim YK, Herlihy JT, Ikeno, Yu BP, Chungg HY. Gene expression of cyclooxygenase in the aging heart. J Gerontol A Biol Sci Med Sci 2001;56(8):B350-B355.
37. Yin X, Wu H, Cheen Y, Kang J. Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol 1998;56:87-93.
38. Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J 2002;16(2):243-245.
39. Kawase M, Watanabe M, Kondo T, Yabu T, Tagguchi Y, Umehara H, Uchiyama T, Mizuno K, Okazaki T. Increase of ceramide in adriamycin-induced HL-60 cell apoptosis: Detection by a novel anti-ceramide antibody. Biochim Biophys Acta 2002;1584(2/3):104-114.
40. Charles AG, Han TY, Liu YY, Hansen N, Giuliiano AE, Cabot MC. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001;47(5):444-450.
41. Feuerstein GZ. Apoptosis-new opportunities for novel therapeutics for heart diseases. Cardiovasc Drugs Ther 2001;15(6):553-554.
42. Brunner F, Andrew P, Wolkart G, Zechner R, Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001;104(25):3097-3102.
43. Alloati G, Penna C, Gallo MP, Levi RC, Bombardelli E, Appendino G. Differential effects of paclitaxel and derivatives on guinea pig isolated heart and papillary muscle. J Pharmacol Exp Ther 1998;284(2):561-567.
44. Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, Gianni L. Paclitaxel and docataxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001;7(6):1511-1515.
45. Garner A, Paine MJ, Rodriguez-Crespo I, Chinjje EC, Ortiz De Montellanoo P, Stratford IJ, Tew DG, Wolf CR. Nitric oxide catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 1999;59(8):1929-1934.
46. Lee DW, Yu BP. Microsomal cytochrome P-450 degradation by in vitro lipid peroxidation. J Nutr Health Aging 1998;2(3):162-166.
47. Holems FA, Rowinsky EK. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 2001;28(4 Suppl 12):8-14.
48. Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, Vale D, Sousa C, Araujo F, Fernandes A, Oliveira J, Passos-Coelho JL. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 2001;48(4):333-337.
49. Danesi R, Conte PF, Del Tacca M. Pharmacokinetic optimization of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet 1999;37(3):195-211.